| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries
|
Kandolf Sekulovic, L.
|
|
2018
|
104 |
C |
p. 201-209
|
artikel
|
| 2 |
A man with recurrent hypovolemic shock on anti–programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy
|
Lee, Seo Young
|
|
2018
|
104 |
C |
p. 104-107
|
artikel
|
| 3 |
A meta-analysis assessing the survival implications of subclassifying T3 rectal tumours
|
Siddiqui, M.R.S.
|
|
2018
|
104 |
C |
p. 47-61
|
artikel
|
| 4 |
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
|
Tio, Martin
|
|
2018
|
104 |
C |
p. 137-144
|
artikel
|
| 5 |
A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours
|
Gazzah, Anas
|
|
2018
|
104 |
C |
p. 1-8
|
artikel
|
| 6 |
A prospective comparative trial of adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts (ASTOUND-2)
|
Tagliafico, Alberto S.
|
|
2018
|
104 |
C |
p. 39-46
|
artikel
|
| 7 |
A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials
|
Ingles Garces, Alvaro H.
|
|
2018
|
104 |
C |
p. 32-38
|
artikel
|
| 8 |
Autoimmune pancreatitis after nivolumab anti–programmed death receptor-1 treatment
|
Dehghani, Lea
|
|
2018
|
104 |
C |
p. 243-246
|
artikel
|
| 9 |
Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?
|
Shanbhag, Satish
|
|
2018
|
104 |
C |
p. 252-253
|
artikel
|
| 10 |
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis
|
Campbell, Matthew T.
|
|
2018
|
104 |
C |
p. 188-194
|
artikel
|
| 11 |
Clinical management of spinal metastases—The Dutch national guideline
|
Bollen, Laurens
|
|
2018
|
104 |
C |
p. 81-90
|
artikel
|
| 12 |
Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis
|
Fachi, Mariana M.
|
|
2018
|
104 |
C |
p. 9-20
|
artikel
|
| 13 |
Evaluation of the prognostic value of the new AJCC 8th edition staging system for patients with pancreatic adenocarcinoma; a need to subclassify stage III?
|
Song, Meiying
|
|
2018
|
104 |
C |
p. 62-69
|
artikel
|
| 14 |
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial
|
Bachet, J.B.
|
|
2018
|
104 |
C |
p. 108-116
|
artikel
|
| 15 |
Hypothalamitis and severe hypothalamic dysfunction associated with anti–programmed cell death ligand 1 antibody treatment
|
Tshuma, N.
|
|
2018
|
104 |
C |
p. 247-249
|
artikel
|
| 16 |
Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy
|
Menzer, Christian
|
|
2018
|
104 |
C |
p. 239-242
|
artikel
|
| 17 |
Influenza vaccination in patients with lung cancer receiving anti–programmed death receptor 1 immunotherapy does not induce immune-related adverse events
|
Wijn, Dirk H.
|
|
2018
|
104 |
C |
p. 182-187
|
artikel
|
| 18 |
Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma
|
Musoro, Jammbe Z.
|
|
2018
|
104 |
C |
p. 169-181
|
artikel
|
| 19 |
Letter comments on a published article in the New England Journal of Medicine
|
Connors, Joseph M.
|
|
2018
|
104 |
C |
p. 250-251
|
artikel
|
| 20 |
Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning
|
Begum, Mursheda
|
|
2018
|
104 |
C |
p. 127-136
|
artikel
|
| 21 |
Meta-analysis of prognostic and predictive factors: Towards individual participant data?
|
Faron, Matthieu
|
|
2018
|
104 |
C |
p. 224-226
|
artikel
|
| 22 |
Observational health research in Europe: understanding the General Data Protection Regulation and underlying debate
|
van Veen, Evert-Ben
|
|
2018
|
104 |
C |
p. 70-80
|
artikel
|
| 23 |
Parenchymal sparing surgery brings treatment of colorectal liver metastases into the precision medicine era
|
Evrard, Serge
|
|
2018
|
104 |
C |
p. 195-200
|
artikel
|
| 24 |
Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma
|
Berger, Mathilde
|
|
2018
|
104 |
C |
p. 227-230
|
artikel
|
| 25 |
Perspectives on window of opportunity trials in head and neck cancer: lessons from the EORTC 90111-24111-NOCI-HNCG study
|
Schmitz, Sandra
|
|
2018
|
104 |
C |
p. 219-223
|
artikel
|
| 26 |
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3
|
Cristofanilli, Massimo
|
|
2018
|
104 |
C |
p. 21-31
|
artikel
|
| 27 |
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
|
Hurvitz, S.A.
|
|
2018
|
104 |
C |
p. 160-168
|
artikel
|
| 28 |
Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018
|
Vangala, Deepak B.
|
|
2018
|
104 |
C |
p. 91-103
|
artikel
|
| 29 |
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers
|
Lunenburg, Carin A.T.C.
|
|
2018
|
104 |
C |
p. 210-218
|
artikel
|
| 30 |
Strong excess risk of pancreatic cancer for low frequency and duration of cigarette smoking: A comprehensive review and meta-analysis
|
Lugo, Alessandra
|
|
2018
|
104 |
C |
p. 117-126
|
artikel
|
| 31 |
Synergistic activity of dasatinib in combination with β-catenin blockade in colorectal cancer cells
|
Mologni, Luca
|
|
2018
|
104 |
C |
p. 231-232
|
artikel
|
| 32 |
To accelerate cancer prevention in Europe: Challenges for cancer registries
|
Zanetti, R.
|
|
2018
|
104 |
C |
p. 151-159
|
artikel
|
| 33 |
Toxicity-induced modification of treatment: what is in a name?
|
Kok, Dieuwertje E.
|
|
2018
|
104 |
C |
p. 145-150
|
artikel
|
| 34 |
Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen
|
Gravis, Gwenaëlle
|
|
2018
|
104 |
C |
p. 236-238
|
artikel
|
| 35 |
Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018
|
Giuliani, Jacopo
|
|
2018
|
104 |
C |
p. 233-235
|
artikel
|
Tijdschrift beschrijving